Retardation of brain aging by chronic treatment with melatonin

S. C. Bondy, D. K. Lahiri, V. M. Perreau, K. Z. Sharman, A. Campbell, J. Zhou, E. H. Sharman

Research output: Contribution to journalArticle

22 Scopus citations


Slowing the functional decline in the aging brain is not only relevant to nonpathological senescence but also to a broad range of neurodegenerative diseases. Although disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) are not found in the young adult, they gradually manifest with increasing age. AD, in particular, is an increasing major public health concern as the population ages; therapies that delay disease onset will markedly reduce overall disease prevalence. Aging of the brain has been repeatedly associated with cumulative oxidative damage to macromolecules and to abnormal levels of inflammatory activity. Melatonin has attained increasing prominence as a candidate for ameliorating these changes occurring during senescence. Recent research has focused on supplementation with dietary melatonin designed to elucidate the specific key intracellular targets of age-related inflammatory events, and the optimal means of affording protection of these targets. This report summarizes the progress made in this area.

Original languageEnglish (US)
Pages (from-to)197-215
Number of pages19
JournalAnnals of the New York Academy of Sciences
StatePublished - Jan 1 2004


  • Antioxidants
  • Brain aging
  • Inflammation
  • Melatonin
  • Neurodegenerative disease

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Retardation of brain aging by chronic treatment with melatonin'. Together they form a unique fingerprint.

  • Cite this

    Bondy, S. C., Lahiri, D. K., Perreau, V. M., Sharman, K. Z., Campbell, A., Zhou, J., & Sharman, E. H. (2004). Retardation of brain aging by chronic treatment with melatonin. Annals of the New York Academy of Sciences, 1035, 197-215.